OR WAIT null SECS
Conferences | GLAUCOMA 360
Glaukos Corporation's COO Chris Calcaterra gives an update on the company's latest 24-month phase 2b data for its iDose TR sustained-release travoprost implant, next steps for securing FDA approval, and his outlook for 2021.
See more Glaucoma 360 coverage
Related Content:
